Diaceutics PLC Purchase/Transfer of Shares and PDMR Shareholdings (1376N)
28 Septiembre 2021 - 1:00AM
UK Regulatory
TIDMDXRX
RNS Number : 1376N
Diaceutics PLC
28 September 2021
28 September 2021
Diaceutics PLC
("Diaceutics" or "the Company")
Purchase and Transfer of Shares and PDMR Shareholdings
Diaceutics PLC , ( AIM: DXRX), the diagnostic commercialisation
company announces that on 27 September 2021, Deborah Davis, the
Chair of Diaceutics, purchased 17,800 ordinary shares of GBP0.002
each in the Company ("Ordinary Shares") at a price of GBP1.11 pence
per Ordinary Share.
In addition, Philip White transferred 150,000 Ordinary Shares to
his father, Philip Michael White.
As a result of the purchase, Deborah's shareholding is 44,800
Ordinary Shares, representing approximately 0.05 % of the Company's
issued share capital and as a result of Philip's transfer, the
beneficial holding of Philip White will be 1,606,389 Ordinary
Shares, representing 1.91 % of the Company's issued share
capital.
Enquiries:
Diaceutics PLC
Philip White, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Robyn Fisher
Kieran Breheny
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of precision medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ ------------------------------------------------------------------------------------------
a. Name Deborah Davis
----------------------------------------------
2 Reason for notification
------------------------------------------ ----------------------------------------------
a. Position/Status Chair
------------------------------------------ ----------------------------------------------
b. Initial notification/ Initial
Amendment
----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
------------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------------ ----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ ------------------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP 0.002 each
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
------------------------------------------ ----------------------------------------------
b. Nature of the Purchase
transaction
------------------------------------------ ----------------------------------------------
c. Price(s) and volume(s) Share purchase:
------------------------------------------ ------------------------------------------
Price(s) Volume(s)
------------------------------------------ --------------------
1.11 17,800
-------------------- --------------------
d. Date of the transaction 27 September 2021
------------------------------------------ ----------------------------------------------
e. Place of the transaction AIM Market of the London Stock Exchange
------------------------------------------ ----------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ -----------------------------------------------------------------------------------------------------
a. Name Philip White
---------------------------------------------------------
2 Reason for notification
------------------------------------------ ---------------------------------------------------------
a. Position/Status Chief Financial Officer
------------------------------------------ ---------------------------------------------------------
b. Initial notification/ Initial
Amendment
---------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
------------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------------ ---------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ -----------------------------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP0.002
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
------------------------------------------ ---------------------------------------------------------
b. Nature of the Transfer of ordinary shares for nil consideration
transaction to PDMR's father
------------------------------------------ ---------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------------ --------------------------
Nil 150,000
---------------------------------------------------------------------------- -------------------------
e. Date of the transaction 27 September 2021
------------------------------------------ ---------------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------------ ---------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFFAALIDFIL
(END) Dow Jones Newswires
September 28, 2021 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
